These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1252 related items for PubMed ID: 19926371

  • 1. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
    MacLaughlin HL, Cook SA, Kariyawasam D, Roseke M, van Niekerk M, Macdougall IC.
    Am J Kidney Dis; 2010 Jan; 55(1):69-76. PubMed ID: 19926371
    [Abstract] [Full Text] [Related]

  • 2. A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease.
    Cook SA, MacLaughlin H, Macdougall IC.
    Nephrol Dial Transplant; 2008 Jan; 23(1):263-8. PubMed ID: 17977872
    [Abstract] [Full Text] [Related]

  • 3. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, ALLIANCE Investigators.
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [Abstract] [Full Text] [Related]

  • 4. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study.
    Othman M, Kawar B, El Nahas AM.
    Nephron Clin Pract; 2009 May; 113(1):c16-23. PubMed ID: 19590231
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD.
    Lo JC, Go AS, Chandra M, Fan D, Kaysen GA.
    Am J Kidney Dis; 2007 Oct; 50(4):552-8. PubMed ID: 17900454
    [Abstract] [Full Text] [Related]

  • 13. Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial.
    Cianciaruso B, Pota A, Bellizzi V, Di Giuseppe D, Di Micco L, Minutolo R, Pisani A, Sabbatini M, Ravani P.
    Am J Kidney Dis; 2009 Dec; 54(6):1052-61. PubMed ID: 19800722
    [Abstract] [Full Text] [Related]

  • 14. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
    Svendsen M, Helgeland M, Tonstad S.
    J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
    [Abstract] [Full Text] [Related]

  • 15. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.
    Rutkowski M, Mann W, Derose S, Selevan D, Pascual N, Diesto J, Crooks P.
    Am J Kidney Dis; 2009 Mar; 53(3 Suppl 3):S86-99. PubMed ID: 19231766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.